Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2013 2
2014 2
2015 1
2016 1
2017 3
2018 1
2019 2
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

13 results
Results by year
Filters applied: . Clear all
Page 1
Prevalence And Clinical Significance Of Oncogenic CD79B And MYD88 Mutations In Primary Testicular Diffuse Large B-Cell Lymphoma: A Retrospective Study In China.
Chen YP, Ke LF, Lu JP, Wang JC, Zhu WF, Chen FF, Lin SF, Xu CW, Wu MJ, Chen G. Chen YP, et al. Onco Targets Ther. 2019 Nov 26;12:10165-10175. doi: 10.2147/OTT.S222189. eCollection 2019. Onco Targets Ther. 2019. PMID: 32063711 Free PMC article.
Primary Type3 (Non-ABC, Non-GCB) Subtype of Extranodal Diffuse Large B-Cell Lymphoma of the Thyroid Bearing No MYD88 Mutation by Padlock Probe Hybridization.
Nishi Y, Kitazawa R, Haraguchi R, Ouchi A, Ueda Y, Kamaoka Y, Yamamoto K, Todo Y, Miyaoka H, Kitazawa S. Nishi Y, et al. Case Rep Oncol. 2017 Jun 14;10(2):508-514. doi: 10.1159/000477489. eCollection 2017 May-Aug. Case Rep Oncol. 2017. PMID: 28690525 Free PMC article.
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.
Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, Yang Y, Cole DE, Melani C, Higham CS, Desai JV, Ceribelli M, Chen L, Thomas CJ, Little RF, Gea-Banacloche J, Bhaumik S, Stetler-Stevenson M, Pittaluga S, Jaffe ES, Heiss J, Lucas N, Steinberg SM, Staudt LM, Wilson WH. Lionakis MS, et al. Cancer Cell. 2017 Jun 12;31(6):833-843.e5. doi: 10.1016/j.ccell.2017.04.012. Epub 2017 May 25. Cancer Cell. 2017. PMID: 28552327 Free PMC article.
Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond.
Rosenquist R, Rosenwald A, Du MQ, Gaidano G, Groenen P, Wotherspoon A, Ghia P, Gaulard P, Campo E, Stamatopoulos K; European Research Initiative on CLL (ERIC) and the European Association for Haematopathology (EAHP). Rosenquist R, et al. Haematologica. 2016 Sep;101(9):1002-9. doi: 10.3324/haematol.2015.134510. Haematologica. 2016. PMID: 27582569 Free PMC article. Review.
Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.
Kelly PN, Romero DL, Yang Y, Shaffer AL 3rd, Chaudhary D, Robinson S, Miao W, Rui L, Westlin WF, Kapeller R, Staudt LM. Kelly PN, et al. J Exp Med. 2015 Dec 14;212(13):2189-201. doi: 10.1084/jem.20151074. Epub 2015 Nov 30. J Exp Med. 2015. PMID: 26621451 Free PMC article.
MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma.
Fernández-Rodríguez C, Bellosillo B, García-García M, Sánchez-González B, Gimeno E, Vela MC, Serrano S, Besses C, Salar A. Fernández-Rodríguez C, et al. Leukemia. 2014 Oct;28(10):2104-6. doi: 10.1038/leu.2014.184. Epub 2014 Jun 6. Leukemia. 2014. PMID: 24903481 No abstract available.
13 results
Jump to page